Companies /Healthcare

Intellia Therapeutics Inc

NASDAQ: NTLA Biotechnology
$12.74
▲ $0.06 (+0.47%) today
Markets closed · 1:37am ET

Q4 2024 Earnings

Reported Feb 27, 2025, 7:45am ET · SEC source
$-1.27
Beat +3.52%
EPS · est. $-1.32
$12.9M
Beat +58.94%
Revenue · est. $8.1M
−30.1%
Trailing market
NTLA vs S&P since report
7 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−12%−6%0+6%Feb 27Feb 28report 7:45am ETearnings−2.2%−10.8%
−12%−6%0+6%Feb 27Feb 28earnings−2.2%−10.8%
NTLA −10.8%S&P 500 −2.2%
−12%−6%0+6%Feb 27Feb 28report 7:45am ETearnings−3.5%−10.8%
−12%−6%0+6%Feb 27Feb 28earnings−3.5%−10.8%
NTLA −10.8%NASDAQ −3.5%
−27%−18%−9%0Feb 26Mar 7report 7:45am ETearnings−4.4%−12.0%
−27%−18%−9%0Feb 26Mar 7earnings−4.4%−12.0%
NTLA −12.0%S&P 500 −4.4%
−27%−18%−9%0Feb 26Mar 7report 7:45am ETearnings−5.9%−12.0%
−27%−18%−9%0Feb 26Mar 7earnings−5.9%−12.0%
NTLA −12.0%NASDAQ −5.9%
+0.56%
Day of report
−7.09%
Next session
−8.84%
One week
−34.53%
30 days

S&P 500 over the same 30 days: −4.39%.

Did NTLA Beat Earnings? Q4 2024 Results

Intellia Therapeutics posted a stronger-than-expected fourth quarter, with its per-share loss of $1.27 coming in narrower than the consensus estimate of $1.32, a beat of 3.52%, while revenue of $12.87 million cleared Wall Street expectations of $8.10 million by nearly 59% and surged 771.6% year over year. The primary driver behind that dramatic revenue swing was a significant recovery in collaboration revenue tied to the Regeneron agreements, which flipped from negative $1.92 million in Q4 2023 to $12.87 million this quarter. The results arrived alongside a January 2025 strategic restructuring in which the company elected to concentrate resources on its two late-stage programs, nexiguran ziclumeran for ATTR amyloidosis and NTLA-2002 for hereditary angioedema, while cutting roughly 27% of its workforce. Looking ahead, enrollment in the Phase 3 MAGNITUDE trial is on track to exceed 550 patients by year-end, and the company's $862 million cash position is expected to fund operations into the first half of 2027.

Key Takeaways
  • Increased collaboration revenue from Regeneron agreements drove $14.8 million revenue improvement year-over-year in Q4
  • Advancement of lead clinical programs drove higher R&D spending
  • Interest income of $10.6 million contributed to reducing net loss

“We are off to an excellent start in 2025 with renewed focus and strong operational execution across our three, pivotal Phase 3 studies. We are excited by the clinical data presented during the fourth quarter. Our Phase 1/2 results in HAE suggest that NTLA-2002 could represent a functional cure for patients with HAE – for the first time a patient has the potential to be both free from attacks and free from chronic therapy. Similarly, the rapid, deep and durable reductions in serum TTR demonstrated to date in our Phase 1 study of nex-z in ATTR represent a highly differentiated profile that may offer patients an opportunity to stabilize or improve their clinical readouts in an otherwise unrelenting, progressive disease.”

Intellia Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

Intellia expects to complete enrollment of the Phase 3 HAELO study in the second half of 2025 and submit a Biologics License Application in the second half of 2026, supporting a planned U.S. launch of NTLA-2002 in 2027. Enrollment in the Phase 3 MAGNITUDE trial for nex-z in ATTR-CM is expected to exceed 550 total patients by year-end. The Phase 3 MAGNITUDE-2 trial was on track to dose its first patient in Q1 2025. The company expects approximately $8.0 million in severance charges in Q1 2025 related to its ~27% workforce reduction. Cash, cash equivalents and marketable securities of approximately $862 million are expected to fund operations into the first half of 2027.

NTLA YoY Financials

Q4 2024 vs Q4 2023 · SEC filings Q4 2023 Q4 2024
$-150,000,000$-100,000,000$-50,000,000$0$1.5M$12.9MRevenue$-133,170,994$-136,447,000Operating Income$-125,790,963$-128,898,000Net Income
$-150,000,000$-100,000,000$-50,000,000$0RevenueOperating IncomeNet Income

NTLA Revenue by Segment

Collaboration Revenue
Collaboration Revenue (Regeneron)

Figures from SEC filings and company reports. Not investment advice.